Should you buy Addus HomeCare (ADUS)?
Updated
Addus HomeCare screens attractively on valuation at a forward price-to-earnings of 12.7x and PEG of 0.91, carries a perfect Piotroski financial health score of 9 out of 9, and has delivered four consecutive earnings beats, while improving technical momentum — rising on-balance volume and improving MACD — and 21.7% upside to the analyst consensus target set up a reward-to-risk ratio of roughly 3.8-to-1.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
At a forward price-to-earnings of 12.7x and a PEG ratio of 0.91, the stock screens as attractively valued relative to its earnings growth rate, while a perfect Piotroski financial health score of 9 out of 9 signals balance sheet and earnings quality in the top tier of its peer group. Valuation breakdown | Forward earnings estimates stay stable or rise, keeping the PEG below 1.2 and the forward P/E below 15x over the next four reported quarters. | →Stable |
| CounterA PEG below 1.0 in a healthcare services business may reflect the market pricing in reimbursement or regulatory risk that compresses long-run growth; the Piotroski score captures historical financial strength but does not guard against prospective margin compression in a competitively contested home-care market. | ||
The company has beaten earnings estimates in each of the last four quarters, with an average positive surprise of roughly 2.8%, demonstrating steady and consistent delivery ahead of consensus expectations. Earnings | The company posts a fifth consecutive earnings beat when it reports in approximately 48 days, with a positive EPS surprise of at least 1%. | →Stable |
| CounterAn average surprise of 2.8% is modest, suggesting tight estimate calibration rather than meaningful operational outperformance; any guidance reset or upward revision to the consensus estimate could make future beats more difficult. | ||
On-balance volume is rising, MACD is improving, and momentum scores well above the threshold for a favorable technical setup, suggesting institutional accumulation is underway even as the stock remains below its 200-day moving average. Momentum breakdown | The stock reclaims the 200-day moving average and on-balance volume continues to rise for at least 3 consecutive months, confirming the accumulation signal. | →Stable |
| CounterThe stock remains below the 200-day moving average with the slope still in decline, meaning the momentum improvement has not yet translated into a confirmed uptrend; a resumption of selling pressure could reverse the on-balance volume signal quickly. | ||
At a forward price-to-earnings of 12.7x and a PEG ratio of 0.91, the stock screens as attractively valued relative to its earnings growth rate, while a perfect Piotroski financial health score of 9 out of 9 signals balance sheet and earnings quality in the top tier of its peer group.
→Stable- Expectation
- Forward earnings estimates stay stable or rise, keeping the PEG below 1.2 and the forward P/E below 15x over the next four reported quarters.
CounterA PEG below 1.0 in a healthcare services business may reflect the market pricing in reimbursement or regulatory risk that compresses long-run growth; the Piotroski score captures historical financial strength but does not guard against prospective margin compression in a competitively contested home-care market.
The company has beaten earnings estimates in each of the last four quarters, with an average positive surprise of roughly 2.8%, demonstrating steady and consistent delivery ahead of consensus expectations.
→Stable- Expectation
- The company posts a fifth consecutive earnings beat when it reports in approximately 48 days, with a positive EPS surprise of at least 1%.
CounterAn average surprise of 2.8% is modest, suggesting tight estimate calibration rather than meaningful operational outperformance; any guidance reset or upward revision to the consensus estimate could make future beats more difficult.
On-balance volume is rising, MACD is improving, and momentum scores well above the threshold for a favorable technical setup, suggesting institutional accumulation is underway even as the stock remains below its 200-day moving average.
→Stable- Expectation
- The stock reclaims the 200-day moving average and on-balance volume continues to rise for at least 3 consecutive months, confirming the accumulation signal.
CounterThe stock remains below the 200-day moving average with the slope still in decline, meaning the momentum improvement has not yet translated into a confirmed uptrend; a resumption of selling pressure could reverse the on-balance volume signal quickly.
▸ Show 1 more pillar▾ Show fewer
Two medium-severity concentration risks are flagged in the company's public filings, which could limit revenue resilience if either dimension comes under pressure.
→Stable- Expectation
- Neither concentration risk materializes into a revenue disruption exceeding 5% of total quarterly revenue over the next 12 months.
CounterMedium-severity concentration risks in healthcare services are often structural characteristics of the business model rather than acute threats; if management has maintained these risk levels over multiple years without a disruption, the risks may be adequately managed.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1At a forward price-to-earnings of 12.7x and a PEG ratio of 0.91, the stock screens as attractively valued relative to its earnings growth rate, while a perfect Piotroski financial health score of 9 out of 9 signals balance sheet and earnings quality in the top tier of its peer group.
Trip ifForward P/E rises above 18x as earnings estimates decline more than 10% from current levels.
- P2The company has beaten earnings estimates in each of the last four quarters, with an average positive surprise of roughly 2.8%, demonstrating steady and consistent delivery ahead of consensus expectations.
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P3On-balance volume is rising, MACD is improving, and momentum scores well above the threshold for a favorable technical setup, suggesting institutional accumulation is underway even as the stock remains below its 200-day moving average.
Trip ifOn-balance volume turns from rising to falling for more than 6 consecutive weeks.
- P4Two medium-severity concentration risks are flagged in the company's public filings, which could limit revenue resilience if either dimension comes under pressure.
Trip ifEither concentration risk produces a disclosed revenue impact exceeding 5% of total quarterly revenue.
How the engine reached this verdict
TrendMatrix's engine output for Addus HomeCare Corporation (ADUS) is HOLD_IF_HOLDING with medium conviction, score 5.6/10 at $97.54. None of the engine's positive-conviction paths (C-quality, D-momentum) cleared their gates — the F-path HOLD reflects balanced signals rather than directional conviction.
Addus HomeCare Corporation (ADUS) sits at overall score 5.6/10 with no actively-failing gates (strongest-cleared: MOMENTUM:5.7>=5.5). HOLD flips toward BUY_WAIT when a positive-conviction path (C-quality or D-momentum) triggers; toward SELL when any of the currently-passing gates drop below threshold or three+ dimensions fall below 4 simultaneously.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $92.66 for existing positions. Asymmetric R:R is 3.66, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bull side: Strong earnings beat streak (4/4); Attractive valuation. On the bear side: Overbought (RSI 81); Below 200-MA, MA slope -2.7%/30d (confirmed downtrend).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates ADUS — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (4/4)
- ▸Attractive valuation
Bear case
- ▸Overbought (RSI 81)
- ▸Below 200-MA, MA slope -2.7%/30d (confirmed downtrend)